CVS Removes Biosimilars From Drug List
One notable change: CVS Caremark has removed the Humira biosimilar Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
UCB's Bimekizumab is Now Available
Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.
Lebrikizumab Maintains Skin Clearance for 2 Years in Atopic Dermatitis
Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.
Cancer Treatment's Checkpoint Inhibitors Are Causing Skin-Related Adverse Events
Checkpoint inhibitors such as pembrolizumab nivolumab are playing a major role in cancer treatment, but they can also produce adverse events that affect the skin.
2 Commerce Drive Cranbury, NJ 08512